The advancement and innovation of new healthcare technologies are developing the platform for the growth of precision medicine market. Since, the announcement of ‘Precision Medicine Initiative’ by the president Barack Obama in January end, 2015, a large number of research and developments are being done for the development of precise drugs, targeted therapeutics, and laboratory tests. Presently, the main focus of the government initiatives is toward oncology, but it is anticipated to target almost all therapeutic area affected by genetic mutations.
The global precision medicine market is expected to reach $ 88 billion by 2022 at a CAGR of 12.0% during the forecast period.
On the basis of sub-markets, Pharmacogenomics is by far the fastest growing segment of global precision medicine market and it is expected to reach $12.0 billion by 2022.
Based on therapeutics, cancer commands the largest market share of global precision medicine market and it is expected to grow at a CAGR of 11.8% during the period 2015 to 2022.
The Americas dominated the global market in 2014 and accounted for $20.63 billion due to the advancement of gene mapping technologies and increasing precision medicine solutions.
Europe and APAC are estimated to show a high growth by the end of forecast period, where large numbers of developments in precision medicine have been noticed in the last few years are. In addition to this, APAC region is also predicted to grow at the highest CAGR of 14.34% from 2015 to 2022.
The leading market players in the global precision medicine market include; Abbott Laboratories (U.S), Almac Group, Ltd. (U.K.), ASURAGEN, Inc. (U.S.), bioMérieux SA (France), Cepheid Inc. (U.S.), GE Healthcare (U.S), GlaxoSmithKline Plc (GSK) (U.K.), Johnson & Johnson (U.S) Medtronic (U.S.) and others.
STUDY OBJECTIVES OF PRECISION MEDICINE MARKET DEVELOPMENT AND DEMAND FORECAST TO 2022 MARKET
Ø To provide insights about factors, influencing and affecting the market growth.
Ø To provide historically and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries.
Ø To provide historically and forecast revenue of the market segments based on products, and sub-segment for global precision medicine market.
Ø To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.
Ø To provide economic factors that influence the global precision medicine market.
• Pharmaceutical companies
• Research Laboratories
• Hospitals & Clinics
• Service Suppliers
• Potential Investors
• Key executive (CEO and COO) and strategy growth manager
• Americas dominated the global precision medicine market in 2015; however, it is expected to grow at a CAGR of 11.6% during 2015 – 2022.
• The companion diagnostics segment holds the largest share, with $10 billion value of the total market in 2015; while it is expected to reach $21.3 billion in 2022, at a CAGR of 13.4% for the period 2015-2022.
• The cancer segments hold the largest share, with $21.1 billion value, of the total market in 2015; while it is expected to reach $46.3 billion in 2022, at a CAGR of 11.8% for the period 2015 – 2022.
• Abbott Laboratories (U.S), GlaxoSmithKline Plc (GSK) (U.K.), Johnson & Johnson (U.S) Medtronic (U.S.), are so far the leading market players for precision medicine market globally
Regional and Country Analysis of precision medicine Market Development and Demand Forecast to 2022 Market
As per the MRFR analysis, the Americas precision medicine market is poised to reach $49.3 billion by 2022, to grow at a CAGR of around XX% during the forecasted period. The European market was valued at $ 9.2 billion in 2015, and expected to reach at $ 21.9 billion by 2022. Asia-Pacific continues to be the fastest growing region during the forecast period.
The reports also cover country level analysis:
• South America
o The U.K.
• Rest of the World (RoW)
Table of Contents ( Key Points )
1 REPORT SCOPE 26
1.1 SCOPE OF THE STUDY 26
1.2 PRECISION MEDICINE: REPORT COVERAGE 27
1.3 RESEARCH METHODOLOGY 29
1.3.1 RESEARCH METHODOLOGY FOR THE GLOBAL MARKET STUDY 30
188.8.131.52 Geographical Analysis 30
184.108.40.206 Demand Side & Supply Side Analysis 31
220.127.116.11 Data Synthesis and Bridging 31
1.3.2 GLOBAL PRECISION MEDICINE: RESEARCH METHODOLOGY 32
1.3.3 KEY DATA POINT SOURCES 33
18.104.22.168 Data Points taken from Secondary Sources 33
22.214.171.124 Data Points taken from Primary Sources 33
1.4 REPORT DESCRIPTION 34
2 EXECUTIVE SUMMARY 38
3 MARKET OVERVIEW 42
3.1 INTRODUCTION 42
3.2 MARKET TIMELINE 42
3.3 KEY PARTICIPANTS, STRATEGIES & DEVELOPMENTS 50
3.3.1 GOVERNMENT AGENCIES 50
3.3.2 ACADEMIC INSTITUTIONS 50
3.3.3 DEVICE & SERVICE PROVIDERS 51
3.4 KEY MARKET STRATEGIES AND DEVELOPMENTS 51
3.4.1 INTRODUCTION 51
3.4.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 52
3.4.3 MERGERS & ACQUISITIONS 54
3.4.4 PRODUCT DEVELOPMENT AND LAUNCH 56
3.4.5 BUSINESS EXPANSION/CONTRACTS 57
3.4.6 PATENTS, APPROVALS AND CERTIFICATIONS 59
3.4.7 OTHERS (EVENTS & RECOGNITIONS) 60
4 MARKET DYNAMICS 61
4.1 INTRODUCTION 61
4.2 MARKET DRIVERS 62
4.2.1 PATIENTS INVOLVEMENT IN PERSONAL HEALTHCARE 62
4.2.2 TECHNOLOGIES DRIVING THE MARKET (E.G. NEXT-GENERATION SEQUENCING TECHNOLOGIES, ULTRA-HIGH THROUGHPUT SEQUENCING) 64
4.2.3 INCREASE IN GENETIC DISEASES 64
4.2.4 POTENTIAL FOR MORE TARGETED THERAPIES 65
4.2.5 INTEGRATION OF BIG DATA HEALTHCARE COMPANIES WITH PHARMA & BIOTECH COMPANIES 65
4.3 MARKET CHALLENGES 66
4.3.1 POTENTIAL THREAT TO PERSONAL DATA 66
4.3.2 HIGH DIAGNOSTIC COST AS A BARRIER 67
4.3.3 POTENTIAL RISK OF HARDWARE OR SOFTWARE FAILURE 68
4.3.4 STRINGENT REGULATIONS AND STANDARDS 68
4.3.5 LACK OF AWARENESS ABOUT THE POSSIBLE APPLICATIONS OF PRECISION MEDICINE 70
4.3.6 REIMBURSEMENT POLICIES AND REGULATORY FRAMEWORK 71
4.3.7 LIMITED KNOWLEDGE ABOUT THE APPLICATION OF TEST AND TECHNIQUES 71
4.3.8 LACK OF RESEARCH AND EVIDENCES CREATING HINDRANCES IN ITS APPLICATION 72
4.4 MARKET OPPORTUNITIES 73
4.4.1 INTRODUCTION OF PRECISION MEDICINE SOLUTIONS IN DEVELOPING ECONOMIES 73
4.4.2 DOWNSIZING THE COST OF GENOME SEQUENCING TO THREE DIGITS 74
5 INDUSTRY DYNAMICS 76
5.1 VALUE CHAIN ANALYSIS 76
5.1.1 DEVICE MANUFACTURER & DRUG PRODUCERS 77
5.1.2 HEALTHCARE PROVIDERS 77
5.1.3 HEALTHCARE ITS OR BIG DATA COMPANIES 77
5.1.4 REGULATORS 77
5.1.5 THIRD PARTY PAYERS 78
5.1.6 PATIENTS 78
5.2 PORTER FIVE FORCE ANALYSIS 78
5.2.1 BARGAINING POWER OF BUYER (PATIENT) 79
5.2.2 BARGAINING POWER OF SUPPLIER 80
5.2.3 THREAT FROM SUBSTITUTE 82
5.2.4 THREAT FROM A NEW ENTRANT 83
5.2.5 INTENSITY OF COMPETITIVE RIVALRY 84
Partner Relations & Marketing Manager
Ph: +1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)